Objectives: The objective of this study was to describe the population pharmacokinetics of cefazolin in plasma and the interstitial fluid of subcutaneous tissue of post-trauma critically ill patients and provide clinically relevant dosing recommendations that result in optimal concentrations at the target site.
Introduction
Effective antibiotic therapy is crucial for improving outcomes in critically ill patients. 1 -3 Whilst much research has been devoted to optimizing antibiotic therapy for infected patients, the ideal use of antibiotics administered for prophylaxis remains poorly investigated. Given that the EPIC II study demonstrated that approximately one-third of critically ill patients receive antibiotics for prophylaxis, 4 prophylaxis is an area where strong data supporting dosing are required. It is likely that sub-optimal administration for this indication could result in failure of prophylaxis or the emergence of resistant pathogens 5 that make later antibiotic treatment highly problematic.
Use of first-generation cephalosporins for prophylaxis in critically ill patients with serious skin and soft tissue injury after major trauma is common. Cefazolin is typically administered at 1 or 2 g intravenously 8-hourly for 24 -72 h. The package insert dose recommendation for antibiotics is based on plasma pharmacokinetic data from non-critically ill patients. Such an approach may be inappropriate given the pharmacokinetic changes that are likely to occur in critically ill patients. 3, 6, 7 Indeed, post-trauma critically ill patients are unlikely to have renal dysfunction, and are in fact at risk of augmented renal clearance, 8 -13 due to their hyperdynamic circulatory state and significant fluid requirements. Dramatically decreased serum albumin concentrations are also common in these patients. 14 For a renally cleared antibiotic like cefazolin, which has high protein binding ( 90%), these changes can severely alter plasma concentrations. 3, 15 The effects of these changes on cefazolin concentrations in the interstitial fluid (ISF) of subcutaneous tissues, which is the site of infection for serious skin and soft tissue injury, are also unknown, but crucial to successful prescription.
Microdialysis is an in vivo sampling technique that has been successfully applied to measure the distribution of antibiotics in the ISF of various tissue sites. 16 In the presence of sepsis and septic shock, antibiotic-specific effects have been described whereby, for piperacillin and meropenem, concentrations in ISF that are 2-to 10-fold lower than plasma concentrations have been observed. 17 -21 For other antibiotics little difference has been demonstrated between plasma and ISF concentrations. 22 Unfortunately, these previous studies have rarely evaluated concentrations at the site of infection. 20, 23 The aim of this study was to describe the population pharmacokinetics of cefazolin in plasma and subcutaneous ISF of critically ill patients with serious skin and soft tissue injuries after major trauma. We then sought to use this model to perform Monte Carlo dosing simulations to determine doses necessary for optimal cefazolin concentrations in ISF.
Patients and methods

Institution where this work was carried out
Department of Intensive Care Medicine, Royal Brisbane and Womens' Hospital, Butterfield Street, Herston, Queensland, Australia 4029.
Setting
This was an observational pharmacokinetic study using convenient sampling at a tertiary referral ICU. Ethics approval was obtained from the local institutional Human Research Ethics Committee (HREC 2007/188). Written informed consent was obtained from either the patient or their nominated substitute decision-maker.
Study population
The inclusion criteria for this study were: (i) age 18 -80 years; and (ii) receiving cefazolin as prophylaxis for skin and soft tissue and bone infections after major trauma. The exclusion criteria were: (i) absence of intra-arterial catheter; (ii) pre-existing renal impairment (defined as a plasma creatinine concentration .171 mmol/L or the need for renal replacement therapy); or (iii) a history of allergy to cephalosporin antibiotics or iodine.
Study protocol
The protocol pertaining to this study has been published in detail elsewhere. 24 In brief, 1 g of cefazolin (DBL Australia, NSW, Australia) diluted in 20 mL of 0.9% sodium chloride, was administered intravenously over 5 min as part of the patient's prescribed therapy. Blood samples to determine plasma cefazolin concentrations were taken pre-dose, at 5 min (end of infusion) and 20, 60, 210 and 360 min. All urine was collected via an indwelling catheter over the dosing interval, following which urine volume and urinary creatinine concentration were determined by laboratory analysis. Plasma creatinine concentrations on the day of investigation were used to calculate the measured CL CR .
Additional clinical and demographic data were collected, including the requirement for mechanical ventilation, vasopressor support, modified SOFA score (excluding the neurological component) and 24 h fluid balance, on the day of drug administration. APACHE II score, body surface area, BMI and ICU and in-hospital mortality were also recorded.
Microdialysis
A microdialysis catheter (CMA 60, 20 kDa dialysis window, Global Scientific, Sweden) was inserted into subcutaneous tissue by an experienced clinician. The catheter was perfused at 1.5 mL/min with a solution of 0.9% sodium chloride and cefalotin (10 mg/L). After a 30 min equilibration period, the first microdialysis sample was taken 1 min prior to the start of the antibiotic infusion with repeat measurements taken at 20, 40, 60, 90, 120, 150, 180, 210, 240, 270, 300, 330 and 360 min. The recovery of cefazolin in the microdialysate solution was interpolated from the loss of internal standard (cefalotin) across the microdialysis membrane: 18, 19, 25 Percentage cefazolin recovery = 100
where C in ¼10 mg/L cefalotin (perfusate) and C out is the measured cefalotin concentration in the microdialysate.
Sample handling, storage and measurement
Blood samples were immediately placed on ice and centrifuged within 60 min at 3000 rpm for 10 min. Plasma and microdialysis samples were stored at -808C until analysis. HPLC was used to measure cefazolin concentrations in plasma and LC -tandem MS to measure concentrations in microdialysate (including cefalotin) as previously described. 23 All bioanalysis techniques were validated and conducted in accordance with the criteria of the US FDA's guidance for industry on bioanalysis (available at www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatory Information/Guidances/UCM070107). To isolate the unbound fraction for analysis, protein-bound cefazolin was removed from the plasma sample with centrifugal filter devices (Centrifree-30K, Merck Millipore, Tullagreen, Ireland).
Population pharmacokinetic modelling
Two-and three-compartment models were developed with the nonparametric adaptive grid (NPAG) algorithm within the Pmetrics package for R (Los Angeles, CA, USA). 26, 27 Elimination from the central compartment and intercompartmental distribution into the ISF compartment and other compartments were modelled as first-order processes using differential equations. Estimates of assay error were included in the modelling process as a polynomial, SD
, with values of 0.02, 0.09, 0 and 0 for plasma data and 0.08, 0.1, 0 and 0 for the ISF data. AUC from 0 to 6 h (AUC 0 -6 ) in plasma and ISF was also calculated. Demographic and clinical characteristics that were considered biologically plausible for affecting cefazolin pharmacokinetics were tested for inclusion as covariates. If inclusion of the covariate resulted in a statistically significant improvement in the log likelihood (P, 0.05) and/or improved the goodness-of-fit plots, it was supported for inclusion.
Model diagnostics
The goodness of fit was assessed by visual inspection of the observedpredicted plot, the coefficient of determination of the linear regression Roberts et al.
of the observed -predicted values and the log-likelihood values from each run. Predictive performance evaluation was based on mean prediction error (bias) and the mean bias-adjusted squared prediction error (imprecision) of the population and individual prediction models in both plasma and ISF compartments.
Probability of target attainment (PTA) for subcutaneous ISF concentrations
Monte Carlo simulations (n ¼ 1000) of subcutaneous ISF concentrations were performed using Pmetrics to determine the PTA with varying MIC for a standard patient with a CL CR of 130 mL/min, serum albumin concentration of 22 g/L and weight of 60 kg. Intravenous doses of 1 g 6-hourly, 1 g 8-hourly, 1 g 12-hourly, 2 g 6-hourly, 2 g 8-hourly and 2 g 12-hourly were simulated. Four different levels of renal function were tested that reflected the broad distribution of values observed in this patient population (CL CR 50, 90, 130 and 215 mL/min). Four different serum albumin concentrations (15, 22, 30 and 44 g/L) were also simulated for a 60 kg patient with a CL CR of 130 mL/min. The PTA for achieving 50% fT .MIC (maintaining concentrations above the MIC for at least 50% of the dosing interval) in plasma and separately in ISF were calculated. 28, 29 Fractional target attainment calculation MIC data for Staphylococcus aureus (a common skin pathogen) from the EUCAST database (available at www.eucast.org; date accessed 14 July 2014) were used to determine fractional target attainment. The fractional target attainment identifies the achievement of target antibiotic exposures by comparing the pharmacodynamic exposure (PTA) against an MIC distribution. The fractional target attainment was calculated using 50% fT .MIC . The PTA for achieving 50% fT .MIC was calculated from the Monte Carlo simulations (n ¼ 1000) for 1 and 2 g doses at 6-hourly, 8-hourly and 12-hourly frequencies for patients with CL CR of 50, 90, 130 and 215 mL/min at MIC values from 0.06 mg/L to 32 mg/L per the EUCAST database. A dosing regimen was considered successful if the fractional target attainment was .85%.
Continuous data are presented as the mean (SD) or median (IQR). Categorical data are presented as counts (%).
Results
Demographic data
Thirty patients were recruited into the study per protocol. 16 Demographic and clinical data are presented in Table 1 . Sampling occurred within 48 h of commencement of therapy for all patients. The cohort was relatively young, with low to moderate illness severity. The vast majority required invasive mechanical ventilation (90%), with 40% requiring vasopressor therapy. No patients died in the ICU; three patients (10%) died in hospital.
Plasma and ISF concentration data
As shown in Figure 1 , unbound plasma and ISF concentrations were frequently below the susceptibility breakpoint for pathogens commonly causative of skin and soft tissue infections (2 mg/L) at the end of the dosing interval. The mean (SD) fraction unbound of cefazolin at 5 min, 1 h and 6 h was 40% (12%), 27% (10%) and 23% (9%), respectively. The median (IQR) microdialysis recovery of cefazolin was 40% (30%-42%). In this patient cohort, the mean (SD) total and unbound plasma and unbound ISF cefazolin AUC 0 -6 values were 184. 8 
Pharmacokinetic model building
The time course of total plasma and unbound ISF concentrations of cefazolin was best described by a three-compartment linear model (Figure 2) . This model included zero-order input of drug into the central compartment. The only covariates that improved the fit of the model were, for cefazolin clearance, CL CR normalized to 100 mL/min and, for V c , serum albumin concentration normalized to 24 g/L and total body weight normalized by 80 kg (to the power of 0.75). When these covariates were added sequentially, each resulted in a statistically significant improvement in the log likelihood from the previous model (CL CR , P,0.01; serum albumin where TVCL is the typical value of cefazolin clearance, TVV c is the typical value of V c , CL is the population parameter estimate of cefazolin clearance, CL CR is measured creatinine clearance, V c is the population parameter estimate of the volume of the central compartment, alb is serum albumin concentration and wt is total body weight. The mean (SD) population pharmacokinetic parameter estimates from the final covariate model are shown in Table 2 . The diagnostic plots to confirm the goodness of fit of the model were considered acceptable and are shown in Figure 3 . The final covariate model was then used for dosing simulations.
Dosing simulations
The Monte Carlo simulations and PTA for achieving 50% fT .MIC in unbound subcutaneous ISF for various cefazolin doses are described in Figure 4 . These simulations generally showed that increasing CL CR was associated with a reduced PTA for the same MIC. Increasing dose and increasing dose frequency resulted in increased PTA. Figure 5 describes the effects of altered serum albumin concentrations on PTA and shows that a greater level of hypoalbuminaemia was associated with a reduced PTA.
Fractional target attainment
The fractional target attainment for the simulated PTAs in subcutaneous ISF for a range of cefazolin doses, dose frequencies and CL CR values against the MIC distribution for S. aureus is shown in Table 3 . These data show that, for a CL CR of 50 mL/min, a 1 g 12-hourly dose is acceptable, covering 88% of isolates, whereas for a patient with a CL CR of 215 mL/min a dose of 2 g 6-hourly is necessary to achieve target cefazolin concentrations for 84% of isolates.
Discussion
To the best of our knowledge, this is the first study that has modelled and simulated target site exposures of an antibiotic in critically ill post-trauma patients. This analysis has demonstrated that increasing CL CR or decreasing serum albumin concentrations reduce the likelihood of achieving optimal cefazolin exposures in ISF. For patients without an elevated CL CR (50 -90 mL/min), a standard dosing regimen of 1 g intravenously 8-hourly commonly results in adequate cefazolin concentrations in ISF for an MIC distribution of a common skin pathogen like S. aureus. In the presence of augmented renal clearance (CL CR .130 mL/min), a much higher dose of 2 g intravenously 6-hourly is required to get similar relative drug exposures in subcutaneous ISF.
Cefazolin is a widely used prophylaxis and treatment option for severe wound infections in post-trauma critically ill patients. It is highly bound to albumin ( 90%), suggesting that in critical illness and/or the presence of hypoalbuminaemia, altered pharmacokinetics are likely. 15, 30, 31 Such effects are likely to be common in critically ill patients, given that 40% will have serum albumin concentrations ,25 g/L.
14 The increased unbound V central , volume of distribution of the central compartment; kct, rate constant for drug distribution from the central to ISF compartment; ktc, rate constant for drug distribution from the ISF to central compartment; kcp, rate constant for drug distribution from the central to peripheral compartment; kpc, rate constant for drug distribution from the peripheral to central compartment.
Roberts et al. Cefazolin PK/PD in ISF of ICU trauma patients plasma concentration that results from such pathophysiological changes should lead to higher pharmacologically active concentrations but also capacity for increased drug clearance. The simulations shown in Figure 5 support the contention that a higher albumin concentration results in better cefazolin exposures in ISF. Without the reservoir of cefazolin bound to albumin to supplement unbound drug that is cleared from the body, patients with lower albumin concentrations are more likely to have reduced pharmacokinetic/pharmacodynamic target attainment. Although plausible, a statistically significant relationship between clearance and serum albumin concentration was not observed in this study. Using microdialysis to measure ISF concentrations, we also observed remarkably similar unbound plasma and unbound ISF concentrations in the drug's elimination phase (Figure 1 ). This result contrasts previous antibiotic studies in critically ill patients, where much lower concentrations in ISF compared with plasma have been described. 17 -19,21 In one study of critically ill patients with septic shock, Joukhadar et al. 17 demonstrated that subcutaneous ISF concentrations of piperacillin could be 5-to 10-fold lower than the concentrations measured in plasma. In the current sample of patients, however, the hyperdynamic physiological response to trauma appears to have resulted in relatively good tissue perfusion and, consequently, antibiotic distribution into ISF. We observed a median 74% (34%-86%) penetration of unbound cefazolin from the plasma into ISF, which is slightly less than that demonstrated in a recent study by Douglas et al., 23 who observed a median 85% (78% -106%) penetration in a cohort of patients undergoing open abdominal aortic aneurysm repair surgery. Other studies using microdialysis to measure subcutaneous ISF penetration of cefazolin have described a mean of (SD) 106% (78%) penetration in patients with lower limb infections 32 and a mean (range) of 70% (68% -103%) to 102% (85% -141%) for morbidly obese versus non-obese patients who were not critically ill. 33 A consequence of the higher unbound concentration in plasma is that it is available for renal elimination from the body and increased drug clearance is likely to result in increased CL CR . Indeed, CL CR was a strong covariate in our model, which is in keeping with its renal elimination characteristics. The higher drug clearance was particularly prominent in patients with elevated renal function, with many patients having very low cefazolin concentrations towards the end of the dosing interval. Indeed, this elevated renal function, also described as augmented renal clearance, is an increasingly described phenomenon in the critically ill, with an incidence of .60% reported in some studies. 8 As a time-dependent antibiotic, for which it is desirable to maintain concentrations above the MIC, these altered pharmacokinetics in the presence of augmented renal clearance are highly problematic for cefazolin. The Monte Carlo simulations provided above highlight this effect. From a comparative perspective, a dose of 1 g intravenously 8-hourly in a patient with a CL CR of 50 mL/min will achieve optimal exposures against 89% of S. aureus, whereas in a patient with augmented renal clearance and a CL CR of 215 mL/min, this will reduce to 65%. Such elevated renal function is being increasingly described in critically ill patients. 9, 10, 34 Risk factors for augmented renal clearance include post-trauma admission, young age and male sex. 8 Indeed, these were all common features of this sample, highlighting that clinicians need to be aware of the need for altered antibiotic dosing requirements in these patients.
We wish to acknowledge the following limitations. These data are from a single centre and therefore may not be representative of the patients admitted to other institutions. Our inclusion criteria were designed to select patients without major renal impairment, as optimal antibiotic dosing in such patients remains problematic. 6, 35 Finally, although this is a large sample size for a pharmacokinetic study, it would be considered small for a clinical study and therefore no conclusions about the clinical implications of these data are possible.
In conclusion, our results indicate that standard dosing of cefazolin is appropriate for achieving optimal concentrations at the target site of infection for post-trauma critically ill patients with normal renal function. However, in the presence of elevated renal function, which is common in this group of patients, or in the presence of severe hypoalbuminaemia, the likelihood of achieving optimal antibiotic exposure decreases significantly, suggesting that higher antibiotic dosing is required for these patients. Cefazolin PK/PD in ISF of ICU trauma patients
